Search Results for "2ed Annual Vaccine Research And Innovation 2012"
Original Source: 2nd Vaccine Research and Innovation Conference
Investigation of vaccine delivery systems, vaccine targets and improved production methods 11th - 12th July 2012, London EC1, UK
Matching Channels
The Scandinavian country of Norway hosts a leading biotechnology industry. In 2009 a $418m stimulus package was established for the industry, to ensure it could continue to grow and ride out the fin...
Pfizer is a global pharmaceutical company, the largest in world based on annual sales. In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have...
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health...
Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...
Matching News
The future outlook for innovation – Christian Moser
Vaccine innovation is by its nature the source of evolution within the vaccine industry. What makes a vaccine work? It’s a combination of all the [...]
Download 7th annual World Vaccine Congress Asia brochure
Aimed at harmonising efforts between governments, NGOs, industry and research institutes for sustainable vaccine programs, World Vaccine Congress Asia is Asia’s most strategic vaccine convention. [....
New study lessens concerns about dengue vaccine production costs
"Research funded by the Dengue Vaccine Initiative (DVI) involving an economic analysis of producing a tetravalent dengue vaccine shows that the cost could be as low as $0.20 per dose with an annual pr...
Pitt scientists developing universal flu vaccine in partnership with Sanofi Pasteur
(Medical Xpress) -- A vaccine strategy that protects against all strains of seasonal influenza and avoids the need for annual vaccination is the ultimate goal of a research collaboration between the U...
NIH awards $7.8 million for innovative HIV vaccine approaches
(NIH/National Institute of Allergy and Infectious Diseases) NIAID has awarded 14 grants totaling $7.8 million in first-year funding for basic research to identify new approaches for designing a safe a...
Vitamin D + TB vaccine: Allies in fight against bladder cancer?
The tuberculosis vaccine is often used as a treatment for bladder cancer, and adding vitamin D might improve the vaccine's effectiveness, according to new research from the University of Rochester Med...
Combination of vitamin D and BCG vaccine improves bladder cancer survival
The tuberculosis vaccine is often used as a treatment for bladder cancer, and adding vitamin D might improve the vaccine's effectiveness, according to new research from the University of Rochester Med...
[VaxInnate] grants [Emergent BioSolutions] US license to manufacture and sell its flu vaccine
[VaxInnate Corp.] has licensed fellow vaccine firm [Emergent BioSolutions Inc.] rights to manufacture and sell its recombinant flu vaccine in the US. VaxInnate will receive development, production, a...
Matching PubMed Articles
On December 12-13, 2011, the United Nations Office for the Coordination of Humanitarian Affairs (OCHA) hosted a humanitarian policy and research conference on the theme of "Risk, Adaptation and Innova...
This paper seeks to give some preliminary evidence on the potential outcome of the pneumococcal vaccine Advance Market Commitment (AMC), with a focus on its impact on innovation in 'emerging' vaccine...
The potential economic value of a 'universal' (multi-year) influenza vaccine.
Please cite this paper as: Lee et al. (2011) The potential economic value of a 'universal' (multi-year) influenza vaccine. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750-2659.2011.00288....
In 2010, the Advisory Committee on Immunization Practices (ACIP) first recommended annual influenza vaccination for all persons aged ≥6 months in the United States. Annual influenza vaccination of a...
Modifying the thermostability of inactivated influenza vaccines.
Respiratory infections caused by influenza viruses spread rapidly, resulting in significant annual morbidity and mortality worldwide. Currently, the most effective public health measure against infect...
